We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2.
- Authors
Armstrong, A.; Eyerich, K.; Conrad, C.; Zhu, Y.; Yang, Y.‐W.; Miller, M.; You, Y.; Shen, Y.‐K.; Foley, P.; Griffiths, C. E. M.; Strober, B.
- Abstract
This document summarizes a study on the use of guselkumab as a treatment for moderate-to-severe psoriasis. The study analyzed data from two Phase 3 trials and found that guselkumab was effective and safe in treating psoriasis. The presence of anti-drug antibodies to guselkumab did not significantly impact the clinical response, and most patients had low antibody levels. The study also found that guselkumab concentrations were similar between patients with and without antibodies. The document cautions against comparing antibody development across different studies or treatments.
- Subjects
IMMUNE response; CLINICAL trials; PSORIASIS; PHARMACOKINETICS
- Publication
Journal of the European Academy of Dermatology & Venereology, 2023, Vol 37, Issue 12, pe1375
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.19309